GSK opens new continuous manufacturing facilities in Singapore

11 Jul 2019

Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

GSK has opened new state-of-the-art manufacturing facilities in Singapore following a S$130m investment.

GSK opens new continuous manufacturing facilities in Singapore

The new facilities are located in GSK's Jurong site and include two continuous manufacturing facilities, and an expansion of one of the site's production buildings. The developments will enable the site, a leading facility within GSK's pharmaceutical supply chain, to accelerate the supply of new breakthrough medicines to patients globally. One of the new continuous manufacturing facilities is part of Jurong's R&D Pilot Plant and will strengthen the site's capability in drug manufacture by allowing faster production of APIs for clinical trials. The first New Chemical Entity (NCE) to be developed at the new facility will be Daprodustat, a new oral treatment for anaemia associated with chronic kidney disease. The new manufacturing process is expected to reduce production time of Daprodustat, enabling faster access to this medicine for patients globally. The expansion of the production building which makes APIs for HIV medicines will strengthen GSK's capability to produce Dolutegravir, a key GSK asset for HIV treatment. The investment has enabled the renewal of critical infrastructure in the production building and has allowed GSK to test and develop digital technologies in the manufacturing process to drive productivity improvement. The investment demonstrates GSK's commitment to Singapore as a key manufacturing and supply site for GSK's global pharmaceutical business and a testbed for advanced manufacturing technology. The investment behind the new facilities is part of the GSK-EDB 10-year Singapore Manufacturing Roadmap. Regis Simard, President Pharmaceuticals Supply Chain, GSK said, "As one of the most innovative cities in the world, Singapore is home to an ecosystem of companies and organisations that are creating and exporting innovative solutions. Innovation is at the heart of GSK, we are glad to invest in scientific and technical excellence in Singapore to develop and launch the next generation of products which meet the needs of patients, payers and consumers." Lim Hock Heng, Vice President & Site Director, Pharmaceuticals Supply Chain Singapore, GSK said, "Advanced manufacturing systems are pivotal for GSK to stay at the forefront of the pharmaceutical manufacturing sector. Further investment in digital manufacturing operations and processes will allow GSK to ensure efficient and high-quality production of our medicines." Chng Kai Fong, Managing Director, EDB said, "Over the years, GSK has continually partnered with Singapore to develop advanced manufacturing technologies, such as continuous manufacturing and digital manufacturing. They have also been a strong partner in training our local talent. These efforts have supported the growth of the industry as a whole and in turn has created diverse and attractive job opportunities for Singapore."

Read More

Related categories

Related tags

Top Stories Market News

Related news

How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

6 Aug 2019

The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.

Read more 
Mylan and Pfizer create new global pharma company

Mylan and Pfizer create new global pharma company

29 Jul 2019

The transaction will allow the new company to expand the geographic reach of Mylan's existing broad product portfolio and future pipeline.

Read more 
Catalent extends global commercial spray drying capabilities in Europe

Catalent extends global commercial spray drying capabilities in Europe

9 Jul 2019

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Brexit's trick or treat on patient safety

Brexit's trick or treat on patient safety

29 Apr 2019

Despite a delayed Brexit, unpredictability adds further complications to the EU FMD regulation.

Read more 
Surge of Indian biosimilars market forecast in 2019

Surge of Indian biosimilars market forecast in 2019

22 Apr 2019

India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.

Read more 
RAPS on delayed Brexit

RAPS on delayed Brexit

26 Mar 2019

The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.

Read more 
Sizeable growth potential for global drug delivery and packaging in 2019

Sizeable growth potential for global drug delivery and packaging in 2019

19 Mar 2019

Patient-centricity, eco-friendly and smart packaging trends marked as the biggest growth drivers and innovations in 2019.

Read more